These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34702583)

  • 1. ROS1 rearrangements in lung adenocarcinomas are defined by diffuse strong immunohistochemical expression of ROS1.
    Fielder T; Butler J; Tierney G; Holmes M; Lam KY; Satgunaseelan L; Colebatch AJ; Mahar A; Gupta R; O'Toole S; Cooper WA
    Pathology; 2022 Jun; 54(4):399-403. PubMed ID: 34702583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
    Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.
    Sholl LM; Sun H; Butaney M; Zhang C; Lee C; Jänne PA; Rodig SJ
    Am J Surg Pathol; 2013 Sep; 37(9):1441-9. PubMed ID: 23887156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
    Selinger CI; Li BT; Pavlakis N; Links M; Gill AJ; Lee A; Clarke S; Tran TN; Lum T; Yip PY; Horvath L; Yu B; Kohonen-Corish MR; O'Toole SA; Cooper WA
    Histopathology; 2017 Feb; 70(3):402-411. PubMed ID: 27599111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ROS1 rearrangements in non-small cell lung cancer: screening by immunohistochemistry using proportion of cells staining without intensity and excluding cases with MAPK pathway drivers improves test performance.
    Prall OWJ; Browning J; Nastevski V; Caporarello S; Bates B; Hewitt CA; Arenas A; Lamb G; Howlett K; Arnolda R; Adeloju R; Stuart S; Xu H; Fellowes A; Fox SB
    Pathology; 2022 Apr; 54(3):279-285. PubMed ID: 34635319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer.
    Cheung CC; Smith AC; Albadine R; Bigras G; Bojarski A; Couture C; Cutz JC; Huang WY; Ionescu D; Itani D; Izevbaye I; Karsan A; Kelly MM; Knoll J; Kwan K; Nasr MR; Qing G; Rashid-Kolvear F; Sekhon HS; Spatz A; Stockley T; Tran-Thanh D; Tucker T; Waghray R; Wang H; Xu Z; Yatabe Y; Torlakovic EE; Tsao MS
    Lung Cancer; 2021 Oct; 160():127-135. PubMed ID: 34509095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histologic and Molecular Characterization of Non-Small Cell Lung Carcinoma With Discordant ROS1 Immunohistochemistry and Fluorescence In Situ Hybridization.
    Wilcock DM; Schmidt RL; Furtado LV; Matynia AP; Deftereos G; Sirohi D
    Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):19-26. PubMed ID: 34534989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements.
    Cha YJ; Lee JS; Kim HR; Lim SM; Cho BC; Lee CY; Shim HS
    PLoS One; 2014; 9(7):e103333. PubMed ID: 25058391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
    Wiesweg M; Eberhardt WEE; Reis H; Ting S; Savvidou N; Skiba C; Herold T; Christoph DC; Meiler J; Worm K; Kasper S; Theegarten D; Hense J; Hager T; Darwiche K; Oezkan F; Aigner C; Welter S; Kühl H; Stuschke M; Schmid KW; Schuler M
    J Thorac Oncol; 2017 Jan; 12(1):54-64. PubMed ID: 27575422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers.
    Yoshida A; Tsuta K; Wakai S; Arai Y; Asamura H; Shibata T; Furuta K; Kohno T; Kushima R
    Mod Pathol; 2014 May; 27(5):711-20. PubMed ID: 24186139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients.
    Hofman V; Rouquette I; Long-Mira E; Piton N; Chamorey E; Heeke S; Vignaud JM; Yguel C; Mazières J; Lepage AL; Bibeau F; Begueret H; Lassalle S; Lalvée S; Zahaf K; Benzaquen J; Poudenx M; Marquette CH; Sabourin JC; Ilié M; Hofman P
    J Thorac Oncol; 2019 Jul; 14(7):1204-1212. PubMed ID: 30999109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer".
    Dyrbekk APH; Warsame AA; Suhrke P; Ludahl MO; Moe JO; Eide IJZ; Lund-Iversen M; Brustugun OT
    Diagn Pathol; 2023 May; 18(1):70. PubMed ID: 37237384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas.
    Augustin J; Gabignon C; Scriva A; Menu L; Calmel C; Scatton O; Paye F; Fléjou JF; Praz F; Cervera P; Wendum D
    Virchows Arch; 2020 Jul; 477(1):33-45. PubMed ID: 32447492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCR.
    Shan L; Lian F; Guo L; Qiu T; Ling Y; Ying J; Lin D
    PLoS One; 2015; 10(3):e0120422. PubMed ID: 25742289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer.
    Viola P; Maurya M; Croud J; Gazdova J; Suleman N; Lim E; Newsom-Davis T; Plowman N; Rice A; Montero MA; Gonzalez de Castro D; Popat S; Nicholson AG
    J Thorac Oncol; 2016 Jul; 11(7):1029-39. PubMed ID: 27179848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
    Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
    J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer.
    Boyle TA; Masago K; Ellison KE; Yatabe Y; Hirsch FR
    Clin Lung Cancer; 2015 Mar; 16(2):106-11. PubMed ID: 25467930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project.
    Speel EM; Dafni U; Thunnissen E; Hendrik Rüschoff J; O'Brien C; Kowalski J; Kerr KM; Bubendorf L; Sansano I; Joseph L; Kriegsmann M; Navarro A; Monkhorst K; Bille Madsen L; Hernandez Losa J; Biernat W; Stenzinger A; Rüland A; Hillen LM; Marti N; Molina-Vila MA; Dellaporta T; Kammler R; Peters S; Stahel RA; Finn SP; Radonic T;
    Lung Cancer; 2024 Aug; 194():107860. PubMed ID: 39002492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of ROS1-positive non-small cell lung cancer on cytological specimens using immunocytochemistry.
    Vlajnic T; Savic S; Barascud A; Baschiera B; Bihl M; Grilli B; Herzog M; Rebetez J; Bubendorf L
    Cancer Cytopathol; 2018 Jun; 126(6):421-429. PubMed ID: 29451745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas: Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods.
    Kao HL; Yeh YC; Lin CH; Hsu WF; Hsieh WY; Ho HL; Chou TY
    Lung Cancer; 2016 Nov; 101():40-47. PubMed ID: 27794407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.